Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emerson C Perin

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
Circulation Research|December 7, 2017
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year AnalysisJay H Traverse, Timothy D Henry, Carl J Pepine, et al.
Circulation|July 20, 2005
Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure: postmortem anatomicopathologic and immunohistochemical findingsHans F R Dohmann, Emerson C Perin, Christina M Takiya, et al.
American Heart Journal|June 7, 2011
A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF)Emerson C Perin, Guilherme V Silva, Timothy D Henry, et al.
Circulation|April 23, 2003
Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failureEmerson C Perin, Hans F R Dohmann, Radovan Borojevic, et al.
American Heart Journal|September 7, 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trialAruni Bhatnagar, Roberto Bolli, Brian H Johnstone, et al.
Circulation Research|April 29, 2018
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure)Roberto Bolli, Joshua M Hare, Keith L March, et al.
Circulation Research|November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trialRobert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Cell Transplantation|November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN TrialDoris A Taylor, Emerson C Perin, James T Willerson, et al.
American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
Circulation Research|December 7, 2017
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year AnalysisJay H Traverse, Timothy D Henry, Carl J Pepine, et al.
Circulation|July 20, 2005
Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure: postmortem anatomicopathologic and immunohistochemical findingsHans F R Dohmann, Emerson C Perin, Christina M Takiya, et al.
American Heart Journal|June 7, 2011
A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF)Emerson C Perin, Guilherme V Silva, Timothy D Henry, et al.
Circulation|April 23, 2003
Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failureEmerson C Perin, Hans F R Dohmann, Radovan Borojevic, et al.
American Heart Journal|September 7, 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trialAruni Bhatnagar, Roberto Bolli, Brian H Johnstone, et al.
Circulation Research|April 29, 2018
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure)Roberto Bolli, Joshua M Hare, Keith L March, et al.
Circulation Research|November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trialRobert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Cell Transplantation|November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN TrialDoris A Taylor, Emerson C Perin, James T Willerson, et al.
American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Pageof 11